Active anti-Pseudomonas treatment was prescribed in 15 of 36 patients 41.7% while treatment for methicillin-resistant Staphylococcus aureus MRSA was indicated in 6 of 36 patients 16.7%.
Se prescribió tratamiento activo frente a Pseudomonas aeruginosa en 15 pacientes de 36 41,7% y frente a Staphylococcus aureus resistente a meticilina SARM en 6 de 36 16,7%.